

# **Heart Attack Diagnostics Market Forecasts to 2032 – Global Analysis By Product (Instruments, Consumables, Software, Services), Test Type, Biomarker, Imaging Modality, Diagnosis Method, Age Group, Application, End User, and By Geography**

<https://marketpublishers.com/r/H990ACABDA54EN.html>

Date: September 2025

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: H990ACABDA54EN

## **Abstracts**

According to Statistics MRC, the Global Heart Attack Diagnostics Market is accounted for \$12.5 billion in 2025 and is expected to reach \$21.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Heart Attack Diagnostics are medical procedures, tests, and devices used to detect and confirm myocardial infarction, a condition caused by restricted blood flow to the heart. These diagnostics include blood tests for cardiac biomarkers, electrocardiograms (ECG), imaging modalities, and stress tests. They help evaluate heart damage, identify blockages, and guide treatment decisions. Accurate and timely heart attack diagnostics are critical for reducing mortality, improving patient outcomes, and preventing complications related to cardiac events.

According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe.

Market Dynamics:

Driver:

Increasing adoption of point-of-care testing devices

The market for heart attack diagnostics is spurred by the rising adoption of point-of-care (POC) testing devices, which enable rapid and accurate detection of cardiac biomarkers

at bedside or emergency settings. These devices reduce turnaround times significantly, ensuring timely clinical intervention and improved patient outcomes. Growing emphasis on decentralized healthcare and emergency response efficiency strengthens their adoption globally. Furthermore, technological advancements in portable diagnostic platforms support broader accessibility, making POC testing a pivotal driver in the heart attack diagnostics landscape.

#### Restraint:

##### Limited access to diagnostics in rural regions

A significant restraint hindering market growth is the limited access to advanced diagnostic facilities in rural and remote regions. Infrastructure gaps, lack of trained healthcare professionals, and high equipment costs restrict adoption of advanced diagnostic tools in these areas. Consequently, delayed detection of cardiac events leads to poor treatment outcomes, widening healthcare disparities. While urban centers benefit from rapid technological adoption, rural healthcare systems continue to face challenges. This disparity slows overall market penetration and limits equitable diagnostic availability.

#### Opportunity:

##### Integration of AI-driven diagnostic platforms

The integration of artificial intelligence (AI) into diagnostic systems presents a promising opportunity for the heart attack diagnostics market. AI-enabled platforms enhance interpretation of complex imaging and biomarker data, enabling faster and more accurate detection of myocardial infarction. Growing investments in digital health and predictive analytics support AI adoption across hospital networks. Additionally, AI-driven decision support tools aid clinicians in triage and treatment planning. As AI technologies mature, their integration enhances precision diagnostics, ultimately revolutionizing cardiac care pathways worldwide.

#### Threat:

##### Risk of misdiagnosis affecting clinical trust levels

Despite technological advancements, the risk of misdiagnosis remains a critical threat in the heart attack diagnostics market. False positives or negatives in biomarker assays or

imaging tests can undermine physician confidence and negatively impact patient safety. Such occurrences may lead to unnecessary treatments or missed interventions, eroding trust in diagnostic systems. Additionally, concerns over variability in test accuracy across different platforms intensify this threat. Sustained clinical validation and standardization are therefore crucial to mitigate risks and preserve diagnostic credibility.

#### Covid-19 Impact:

The COVID-19 pandemic significantly disrupted the heart attack diagnostics market, with hospitals prioritizing COVID care and delaying elective cardiac testing. Patient reluctance to visit healthcare facilities further reduced diagnostic volumes. However, the crisis accelerated adoption of point-of-care testing and telehealth-driven cardiac monitoring solutions. Post-pandemic recovery has seen renewed emphasis on early cardiac diagnostics, with healthcare systems investing in resilient diagnostic infrastructure. Consequently, COVID-19 served as both a short-term setback and a long-term catalyst for innovation and decentralization in cardiac diagnostics.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, owing to their widespread use in hospitals, diagnostic laboratories, and emergency care centers. Instruments such as analyzers, imaging devices, and biomarker detection systems form the backbone of cardiac diagnostics, ensuring accurate and timely assessments. Growing demand for technologically advanced and automated diagnostic instruments further consolidates their dominance. Moreover, continuous innovation in imaging modalities and biomarker platforms reinforces the instruments segment as the market's leading contributor.

The echocardiogram segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the echocardiogram segment is predicted to witness the highest growth rate, impelled by its non-invasive nature and ability to provide real-time cardiac imaging. The increasing prevalence of cardiovascular diseases and preference for ultrasound-based diagnostics fuel demand. Advancements in 3D and portable echocardiography systems enhance clinical accuracy and accessibility. Additionally, echocardiograms are becoming integral in emergency and outpatient settings for rapid heart function assessment. This convergence of innovation and adoption establishes echocardiography as the fastest-growing diagnostic segment.

### Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by its expanding patient pool, rising cardiovascular disease prevalence, and growing healthcare infrastructure. Increasing government initiatives to strengthen early disease detection systems further enhance adoption. Moreover, the presence of cost-effective diagnostic solutions in emerging economies boosts accessibility. Rapid urbanization and lifestyle changes exacerbate cardiac risk factors, fueling diagnostic demand. Collectively, these elements position Asia Pacific as the leading regional market in heart attack diagnostics.

### Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high diagnostic awareness, and rapid technology adoption. Strong presence of leading diagnostic companies and extensive R&D investments accelerate innovation in cardiac testing solutions. Favorable reimbursement frameworks support market penetration of advanced diagnostics. Additionally, growing demand for precision diagnostics and digital health integration amplifies adoption. As cardiovascular burden continues to rise, North America emerges as the fastest-expanding regional market.

### Key players in the market

Some of the key players in Heart Attack Diagnostics Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Thermo Fisher Scientific Inc., Qiagen N.V., Randox Laboratories, Ortho Clinical Diagnostics, Becton, Dickinson and Company, CardioDx Inc., Biomerica Inc., Luminex Corporation, BioMerieux SA, Nova Biomedical, Nihon Kohden Corporation, Response Biomedical Corporation, and Critical Diagnostics.

### Key Developments:

In May 2025, Roche Diagnostics (F. Hoffmann-La Roche Ltd) received FDA 510(k) clearance for an enhanced version of its Elecsys® Troponin T high-sensitivity test, aimed at providing even more precise risk stratification for patients presenting with chest pain in the emergency department.

In April 2025, Siemens Healthineers announced the U.S. launch of its Atellica® CI1900 Integrated Solution, which combines core laboratory and cardiac testing to deliver a consolidated troponin result from a single platform, improving workflow efficiency for heart attack diagnosis.

In March 2025, Abbott Laboratories initiated a major clinical study across 100 sites in the U.S. and Europe to expand the clinical claims for its Alinity i High-Sensitivity Troponin-I assay, focusing on rapid rule-out protocols to help reduce emergency room overcrowding.

#### Products Covered:

Instruments

Consumables

Software

Services

#### Test Types Covered:

Electrocardiogram (ECG)

Blood Tests

Echocardiogram

Coronary Angiography

#### Biomarkers Covered:

Troponin

Creatine Kinase-MB (CK-MB)

Myoglobin

C-Reactive Protein (CRP)

Brain Natriuretic Peptide (BNP)

#### Imaging Modalities Covered:

Echocardiography

Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Nuclear Imaging

X-ray

#### Diagnosis Methods Covered:

Laboratory Testing

Imaging Testing

Point-of-Care Testing

#### Age Groups Covered:

Below 40 Years

Above 60 Years

#### Applications Covered:

Emergency Diagnosis

Risk Assessment

Therapy Monitoring

Research Applications

End Users Covered:

Hospitals

Diagnostic Centers

Ambulatory Surgical Centers

Research Laboratories

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

## Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

### **Free Customization Offerings:**

All the customers of this report will be entitled to receive one of the following free customization options:

#### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

#### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

#### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

## **5 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY PRODUCT**

- 5.1 Introduction
- 5.2 Instruments
- 5.3 Consumables
- 5.4 Software
- 5.5 Services

## **6 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY TEST TYPE**

- 6.1 Introduction
- 6.2 Electrocardiogram (ECG)
- 6.3 Blood Tests
- 6.4 Echocardiogram
- 6.5 Coronary Angiography

## **7 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY BIOMARKER**

- 7.1 Introduction
- 7.2 Troponin
- 7.3 Creatine Kinase-MB (CK-MB)
- 7.4 Myoglobin
- 7.5 C-Reactive Protein (CRP)
- 7.6 Brain Natriuretic Peptide (BNP)

## **8 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY IMAGING MODALITY**

- 8.1 Introduction
- 8.2 Echocardiography
- 8.3 Computed Tomography (CT)
- 8.4 Magnetic Resonance Imaging (MRI)
- 8.5 Nuclear Imaging
- 8.6 X-ray

## **9 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY DIAGNOSIS METHOD**

- 9.1 Introduction
- 9.2 Laboratory Testing

9.3 Imaging Testing

9.4 Point-of-Care Testing

## **10 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY AGE GROUP**

10.1 Introduction

10.2 Below 40 Years

10.3 Above 60 Years

## **11 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY APPLICATION**

11.1 Introduction

11.2 Emergency Diagnosis

11.3 Risk Assessment

11.4 Therapy Monitoring

11.5 Research Applications

## **12 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY END USER**

12.1 Introduction

12.2 Hospitals

12.3 Diagnostic Centers

12.4 Ambulatory Surgical Centers

12.5 Research Laboratories

## **13 GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY GEOGRAPHY**

13.1 Introduction

13.2 North America

13.2.1 US

13.2.2 Canada

13.2.3 Mexico

13.3 Europe

13.3.1 Germany

13.3.2 UK

13.3.3 Italy

13.3.4 France

13.3.5 Spain

13.3.6 Rest of Europe

## 13.4 Asia Pacific

13.4.1 Japan

13.4.2 China

13.4.3 India

13.4.4 Australia

13.4.5 New Zealand

13.4.6 South Korea

13.4.7 Rest of Asia Pacific

## 13.5 South America

13.5.1 Argentina

13.5.2 Brazil

13.5.3 Chile

13.5.4 Rest of South America

## 13.6 Middle East & Africa

13.6.1 Saudi Arabia

13.6.2 UAE

13.6.3 Qatar

13.6.4 South Africa

13.6.5 Rest of Middle East & Africa

## 14 KEY DEVELOPMENTS

14.1 Agreements, Partnerships, Collaborations and Joint Ventures

14.2 Acquisitions & Mergers

14.3 New Product Launch

14.4 Expansions

14.5 Other Key Strategies

## 15 COMPANY PROFILING

15.1 Abbott Laboratories

15.2 Siemens Healthineers

15.3 F. Hoffmann-La Roche Ltd.

15.4 GE Healthcare

15.5 Philips Healthcare

15.6 Bio-Rad Laboratories Inc.

15.7 Beckman Coulter (Danaher Corporation)

15.8 Thermo Fisher Scientific Inc.

15.9 Qiagen N.V.

- 15.10 Randox Laboratories Ltd.
- 15.11 Ortho Clinical Diagnostics
- 15.12 Becton, Dickinson and Company (BD)
- 15.13 CardioDx Inc.
- 15.14 Biomerica Inc.
- 15.15 Luminex Corporation
- 15.16 BioMerieux SA
- 15.17 Nova Biomedical
- 15.18 Nihon Kohden Corporation
- 15.19 Response Biomedical Corporation
- 15.20 Critical Diagnostics

## List Of Tables

### LIST OF TABLES

Table 1 Global Heart Attack Diagnostics Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Heart Attack Diagnostics Market Outlook, By Product (2024-2032) (\$MN)

Table 3 Global Heart Attack Diagnostics Market Outlook, By Instruments (2024-2032) (\$MN)

Table 4 Global Heart Attack Diagnostics Market Outlook, By Consumables (2024-2032) (\$MN)

Table 5 Global Heart Attack Diagnostics Market Outlook, By Software (2024-2032) (\$MN)

Table 6 Global Heart Attack Diagnostics Market Outlook, By Services (2024-2032) (\$MN)

Table 7 Global Heart Attack Diagnostics Market Outlook, By Test Type (2024-2032) (\$MN)

Table 8 Global Heart Attack Diagnostics Market Outlook, By Electrocardiogram (ECG) (2024-2032) (\$MN)

Table 9 Global Heart Attack Diagnostics Market Outlook, By Blood Tests (2024-2032) (\$MN)

Table 10 Global Heart Attack Diagnostics Market Outlook, By Echocardiogram (2024-2032) (\$MN)

Table 11 Global Heart Attack Diagnostics Market Outlook, By Coronary Angiography (2024-2032) (\$MN)

Table 12 Global Heart Attack Diagnostics Market Outlook, By Biomarker (2024-2032) (\$MN)

Table 13 Global Heart Attack Diagnostics Market Outlook, By Troponin (2024-2032) (\$MN)

Table 14 Global Heart Attack Diagnostics Market Outlook, By Creatine Kinase-MB (CK-MB) (2024-2032) (\$MN)

Table 15 Global Heart Attack Diagnostics Market Outlook, By Myoglobin (2024-2032) (\$MN)

Table 16 Global Heart Attack Diagnostics Market Outlook, By C-Reactive Protein (CRP) (2024-2032) (\$MN)

Table 17 Global Heart Attack Diagnostics Market Outlook, By Brain Natriuretic Peptide (BNP) (2024-2032) (\$MN)

Table 18 Global Heart Attack Diagnostics Market Outlook, By Imaging Modality (2024-2032) (\$MN)

Table 19 Global Heart Attack Diagnostics Market Outlook, By Echocardiography (2024-2032) (\$MN)

Table 20 Global Heart Attack Diagnostics Market Outlook, By Computed Tomography (CT) (2024-2032) (\$MN)

Table 21 Global Heart Attack Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) (\$MN)

Table 22 Global Heart Attack Diagnostics Market Outlook, By Nuclear Imaging (2024-2032) (\$MN)

Table 23 Global Heart Attack Diagnostics Market Outlook, By X-ray (2024-2032) (\$MN)

Table 24 Global Heart Attack Diagnostics Market Outlook, By Diagnosis Method (2024-2032) (\$MN)

Table 25 Global Heart Attack Diagnostics Market Outlook, By Laboratory Testing (2024-2032) (\$MN)

Table 26 Global Heart Attack Diagnostics Market Outlook, By Imaging Testing (2024-2032) (\$MN)

Table 27 Global Heart Attack Diagnostics Market Outlook, By Point-of-Care Testing (2024-2032) (\$MN)

Table 28 Global Heart Attack Diagnostics Market Outlook, By Age Group (2024-2032) (\$MN)

Table 29 Global Heart Attack Diagnostics Market Outlook, By Below 40 Years (2024-2032) (\$MN)

Table 30 Global Heart Attack Diagnostics Market Outlook, By Above 60 Years (2024-2032) (\$MN)

Table 31 Global Heart Attack Diagnostics Market Outlook, By Application (2024-2032) (\$MN)

Table 32 Global Heart Attack Diagnostics Market Outlook, By Emergency Diagnosis (2024-2032) (\$MN)

Table 33 Global Heart Attack Diagnostics Market Outlook, By Risk Assessment (2024-2032) (\$MN)

Table 34 Global Heart Attack Diagnostics Market Outlook, By Therapy Monitoring (2024-2032) (\$MN)

Table 35 Global Heart Attack Diagnostics Market Outlook, By Research Applications (2024-2032) (\$MN)

Table 36 Global Heart Attack Diagnostics Market Outlook, By End User (2024-2032) (\$MN)

Table 37 Global Heart Attack Diagnostics Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 38 Global Heart Attack Diagnostics Market Outlook, By Diagnostic Centers (2024-2032) (\$MN)

Table 39 Global Heart Attack Diagnostics Market Outlook, By Ambulatory Surgical Centers (2024-2032) (\$MN)

Table 40 Global Heart Attack Diagnostics Market Outlook, By Research Laboratories (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Heart Attack Diagnostics Market Forecasts to 2032 – Global Analysis By Product (Instruments, Consumables, Software, Services), Test Type, Biomarker, Imaging Modality, Diagnosis Method, Age Group, Application, End User, and By Geography

Product link: <https://marketpublishers.com/r/H990ACABDA54EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H990ACABDA54EN.html>